{"entity":{"id":"nct04130516","kind":"trial","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","aka":[],"tldr":"A phase 1/2 trial of LNS8801 and Pembrolizumab in advanced solid tumours, run by Linnaeus Therapeutics, Inc., active and no longer recruiting.","summary":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab is a phase 1/2 interventional study registered as NCT04130516 by Linnaeus Therapeutics, Inc., with 200 participants enrolled, started 2019-10-21 and due to reach its primary completion in 2026-06-30. Interventions recorded: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER and Pembrolizumab - anti-PD-1 antibody.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04130516","url":"https://clinicaltrials.gov/study/NCT04130516"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lns8801","pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04130516","phase":"1/2","setting":"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab","sponsor":"Linnaeus Therapeutics, Inc.","enrolled":200,"outcomes":[]},"route":"/trials/nct04130516/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}